Navigation Links
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results from the RE-NOVATE(TM) trial demonstrated that oral dabigatran etexilate once daily, administered for an average of 33 days, was non-inferior to enoxaparin, also administered for an average of 33 days, in preventing venous thromboembolism (VTE) and all-cause mortality after total hip replacement surgery. In this trial, the rate of major bleeding associated with dabigatran etexilate was similar to enoxaparin. The incidence of liver enzyme elevations and acute coronary events during the treatment or during the follow-up period did not differ significantly between the treatment groups. These data were presented at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) today.(i) In clinical trials, dabigatran etexilate is given orally once daily and does not require titration or coagulation monitoring.

Results of the RE-NOVATE trial showed that both oral doses (220mg; 150 mg) of dabigatran etexilate were non-inferior to injected enoxaparin at reducing the risk of thromboembolic disease after primary elective total hip replacement surgery when given for the extended average time period of 33 days. The incidences for the primary efficacy composite endpoint of total VTE and all-cause mortality were 6.0% (dabigatran 220 mg), 8.6% (dabigatran 150 mg), and 6.7% (enoxaparin 40 mg). The incidences of total VTE and all-cause mortality in both dabigatran dose groups were within the pre-specified non- inferiority margin of 7.7%. Safety was evaluated for 3,463 patients receiving study treatment. The incidences of major bleeding events were similar in all treatment groups, 2.0% (dabigatran 220 mg), 1.3% (dabigatran 150 mg), and 1.6% (enoxaparin 40 mg).

Also presented at ISTH was a pooled analysis of major VTE and VTE-related mortality after primary elective knee and hip replacement surgery across more than 8,000 randomiz
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:11/26/2014)... NEW YORK and HERZLIYA PITUACH, Israel, Nov. ... IMNP; "Immune" or "the Company"), a clinical stage ... commercialization of targeted therapeutics for the treatment of ... of its previously announced underwritten public offering of ... share of the Company,s common stock, par value ...
(Date:11/24/2014)... Nov. 24, 2014  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 3, 2014 at The New ... . A live webcast of the Company,s presentation ... feature an overview of the company by Pat Mackin ...
(Date:11/24/2014)... Colo. , Nov. 24, 2014 ... Inc. (NYSE MKT: AMPE), today announced the presentation ... RedoxSYS™ Diagnostic System as a broadly applicable and ... (ORP) in the body in response to injury, ... were performed in collaboration with Luoxis, academic and ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... November 26, 2014 Call 866-997-4948 (Us-Canada ... or email the details on sales(at)researchmoz(dot)us , Researchmoz.us ... drug discovery market 2014" with deep study of the ... result of high blood sugar. The global glucose monitoring ... to the growing number of diabetics in the world. ...
(Date:11/26/2014)... Baton Rouge, Louisiana (PRWEB) November 26, 2014 ... and neck pain relief and specialists in minimally ... Dr. K. Samer Shamieh into the rapidly growing ... management specialists. The addition coincides with the ... cutting-edge, reliable medical treatment for Louisiana residents who ...
(Date:11/26/2014)... News) -- Youngsters who enter puberty early are at ... Early puberty was linked with a number of factors ... anxiety levels, according to the researchers. Early puberty was ... family and peers, and having friends who were prone ... the study found an association between early puberty and ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2
... the drug Rimonabant (Acomplia) a selective cannabinoid receptor blocker ... . Supplementation with 20 milligrams of rimonabant a day ... waist circumference -- a marker of cardiovascularly dangerous visceral ... the prevalence of metabolic syndrome in overweight/obese patients. ...
... to avoid medical mistakes, but now it seems computerized prescription ... is known that adverse drug events injure or kill more ... are trying to cut back on that number is with ... use of computerized systems may actually be leading to more ...
... gradually increased recommendations for daily calcium intake, largely from ... to promote healthy bones and prevent osteoporosis. But a ... of milk or other dairy products was not necessarily ... of at least 400 milligrams per day. ,Other ...
... us have not forgotten the thalidomide tragedy thalidomide in the ... morning sickness // to pregnant mothers and resulted in seal ... future use for the infamous medication: helping cancer patients maintain ... in pancreatic cancer patients and was seen to help ...
... cell research that will help in numerous therapies using stem ... human embryonic stem cells in the laboratory. ,Human ... role in regeneration of cells for therapeutic use. However, while ... animal cells and serum and run the risk of being ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
Cached Medicine News:
... Coat-A-Count Estradiol is,a ... for in vitro,diagnostic use ... estradiol in serum, for ... and,for monitoring of ovulation ...
... Estradiol (E2) is the most potent, ... estrogen produced by the ovary [1]. In ... [1,2], and from estrone, a less potent ... are interconverted in many body tissues. In ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
For the quantitative measurement of CKMB, Myoglobin, and Troponin-I in human serum....
Medicine Products: